Search
Vaccines Treatment Options in North Carolina
A collection of 182 research studies where Vaccines is the interventional treatment. These studies are located in the North Carolina, United States. Vaccines is used for conditions such as Influenza, COVID-19 and Hepatitis B.
169 - 180 of 182
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants
Completed
The primary objective of this phase 3b study is to evaluate the safety and tolerability of Novartis MenACWY conjugate vaccine when administered with routine infant vaccinations to healthy infants
Gender:
ALL
Ages:
Between 55 days and 89 days
Trial Updated:
05/13/2013
Locations: 56 Cary Pediatrics 1001 Crescent Green Dr., Cary, North Carolina +6 locations
Conditions: Meningitis, Meningococcal Infection
Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
Terminated
RATIONALE: Vaccines made from tumor tissue may make the body build an immune response and kill tumor cells.
PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have stage III or stage IV ovarian epithelial cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/10/2013
Locations: Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina +2 locations
Conditions: Ovarian Cancer
Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects
Completed
Primary Objective:
To describe the immune response to a single administration of 2 formulations of the investigational cell-based influenza vaccines in healthy adult subjects.
Secondary Objective:
To describe the safety following a single administration of 2 formulations of the investigational cell-based influenza vaccines in healthy adult subjects.
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
12/13/2012
Locations: Not set, Cary, North Carolina +1 locations
Conditions: Influenza, Orthomyxoviruses, Myxovirus Infection
A Phase I Study of Ovarian Cancer Peptides Plus GM-CSF and Adjuvant With Ovarian, Tubal or Peritoneal Cancer
Completed
This study will evaluate the safety of administering a peptide vaccine consisting of twelve different tumor-rejection antigens known to be present on ovarian tumor cells. The vaccine is designed to elicit immune responses against twelve different pathways that are essential to tumor growth, survival and metastasis.HLA-A2+ is a required criteria for subject eligibility.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/15/2012
Locations: Duke Comprehensive Cancer Center, Durham, North Carolina
Conditions: Epithelial Ovarian, Tubal or Peritoneal Cancer
A Study of the Effects of RoActemra/Actemra on Vaccination in Patients With Rheumatoid Arthritis on Background Methotrexate (VISARA)
Completed
This randomized, parallel-group, open-label study will evaluate the effect of Actemra (tocilizumab) on vaccination in patients with active rheumatoid arthritis who have an inadequate response to methotrexate and who have had an inadequate clinical response or were intolerant to treatment with one or more anti-tumor necrosis factor (anti-TNF) therapies.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
11/12/2012
Locations: Not set, Belmont, North Carolina +2 locations
Conditions: Rheumatoid Arthritis
Safety and Efficacy of an H1N1 Influenza Vaccine in People With Asthma
Completed
The purpose of this study is to assess the safety and the body's immune response (body's defense against disease) to an experimental H1N1 influenza vaccine in people with asthma. The study will enroll 350, and possibly up to 400 healthy adults ages 12 and older with mild, moderate, or severe asthma. Participants will be randomly assigned to 1 of 2 possible vaccine groups: group 1 will receive 15 mcg of H1N1 vaccine; group 2 will receive 30 mcg of H1N1 vaccine given as two 15 mcg injections. Both... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
08/08/2012
Locations: Wake Forest University School of Medicine, Winston-Salem, North Carolina
Conditions: H1N1 Influenza Virus
Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older
Terminated
The aim of this study is to determine the efficacy of Fluzone High Dose vaccine and that of Fluzone® vaccine in the elderly.
Primary objective:
To measure the efficacy of the vaccine, defined as the prevention of laboratory-confirmed influenza caused by viral types/subtypes that are antigenically similar to those contained in the respective annual vaccine formulations.
Secondary objectives:
* To compare the clinical efficacy of Fluzone High Dose vaccine with that of Fluzone® vaccine in elder... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/24/2012
Locations: Not set, Cary, North Carolina +7 locations
Conditions: Influenza
S0122: Combination Chemotherapy, Radiation Therapy, and Vaccine Therapy in Limited-Stage Small Cell Lung Cancer
Terminated
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high energy x-rays to damage tumor cells. Vaccines may make the body build an immune response to kill tumor cells. Combining chemotherapy and radiation therapy with vaccine therapy may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining chemotherapy and radiation therapy with vaccine therapy in treating patients who hav... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2012
Locations: CCOP - Southeast Cancer Control Consortium, Winston-Salem, North Carolina
Conditions: Lung Cancer
NicVAX/Placebo as an Aid for Smoking Cessation
Completed
The purpose of this study is to evaluate NicVAX as an aid to smoking cessation for long term abstinence.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/08/2012
Locations: NicVAX Investigator, Raleigh, North Carolina
Conditions: Smoking Cessation, Smoking, Tobacco Cessation
Double Blind, Safety and Immunogenicity Study of Recombinant Botulinum Vaccine A/B
Completed
This Phase 2 study is a double blind, placebo-controlled, randomized, multicenter investigation of rBV A/B-40 vaccine or placebo in healthy adults, using two different three-dose dosing schedules.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
11/28/2011
Locations: Wake Research Associates, Raleigh, North Carolina
Conditions: Botulism Vaccine
A Study of Different Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly
Completed
The purpose of the study is to evaluate different doses of the Influenza A/H1N1 pandemic vaccine in adults and the elderly.
Primary Objectives:
* To describe the immunogenicity of the candidate vaccines after a single injection.
* To describe the safety of the candidate vaccines after a single injection.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/26/2011
Locations: Not set, Raleigh, North Carolina
Conditions: Influenza, Swine-origin A/H1N1 Influenza
Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS
Completed
The objective of this study is to compare the safety, tolerability and immunologic response to a dose of 23vPS or 13vPnC given one year after either 13vPnC or 23vPS in subjects that have never received a previous dose of 23vPS.
Gender:
ALL
Ages:
Between 60 years and 64 years
Trial Updated:
07/18/2011
Locations: Pfizer Investigational Site, Raleigh, North Carolina
Conditions: Pneumococcal Vaccines
169 - 180 of 182